APR 30 2026
Axsome Therapeutics — Auvelity (dextromethorphan/bupropion) $AXSM
for Agitation in Alzheimer's dementia
FDA approved Auvelity (dextromethorphan/bupropion) for agitation associated with dementia due to Alzheimer's disease.
About
Alzheimer's disease progressively damages memory and cognitive function, often leading to mood swings, social withdrawal, and behavioral challenges like agitation. Auvelity combines dextromethorphan, which affects brain signaling, with bupropion, a drug that helps sustain dextromethorphan's activity in the body. This dual-action approach may help regulate the overactive brain signals linked to agitation, potentially improving daily life for those with Alzheimer's-related distress.
Pivotal trial
This trial is a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease.
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Auvelity
- Axsome Sees Auvelity Momentum, Alzheimer's Agitation Approval Driving Growth Outlook, Oppenheimer Says - Moomoo
- Should New AUVELITY Anxious-Distress Data From ASCP 2026 Require Action From Axsome (AXSM) Investors? - simplywall.st
- Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting - Yahoo Finance
- New AUVELITY depression data, sleep apnea study head to ASCP 2026 - Stock Titan
- Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting - Toronto Star
Sponsor Watch — recent news on Axsome Therapeutics
- Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
- Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch
- How The Axsome Therapeutics (AXSM) Story Is Shifting After Auvelity And AXS 05 Developments
- AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales